Everest Medicines Limited recently announced positive results from an ongoing Phase 1b/2a clinical trial of their next-generation covalent reversible Bruton's tyrosine kinase $(BTK.AU)$ inhibitor, EVER001 (previously known as XNW1011), for the treatment of primary membranous nephropathy (pMN). These results were presented at the 62nd Congress of the European Renal Association (ERA 2025) during a focused oral session. The company continues to advance its innovative mRNA cancer vaccine and in-vivo CAR-T programs, while also focusing on increasing sales and expanding the reach of its other products such as NEFECON® and XERAVA®.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。